Trial
NCT02988843
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Germ Cell Tumor
Intervention
Brentuximab Vedotin
Why stopped
Funding Unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-10